Hypothesis

NLRP3 activation in aged macrophages drives mitochondrial DNA (mtDNA) release into the cytosol, which then engages the cGAS‑STING pathway to boost IL‑6 trans‑signaling via soluble IL‑6R. This amplified IL-6 signal sustains STAT3‑mediated transcription of a senescence‑associated secretory phenotype (SASP), creating a feed‑forward loop that locks cells into immunosenescence. Blocking mtDNA efflux or STING signaling should break the loop and restore youthful cytokine responsiveness even when NLRP3 remains active.

Mechanistic Rationale

• NLRP3 inflammasome assembly is triggered by mitochondrial dysfunction, oxidized mtDNA and ROS, leading to caspase‑1 activation and IL-1β maturation [1].
• Caspase-1 also cleaves gasdermin D, forming pores that permit mtDNA efflux into the cytosol [1].
• Cytosolic mtDNA activates cGAS, producing cGAMP that stimulates STING, which induces IRF3‑driven IFN‑β and NF‑κB‑dependent transcription of IL-6 and IL-6R [2].
• IL-6 released can act in trans‑signaling mode when bound to soluble IL-6R, activating STAT3 in neighboring cells and reinforcing SASP gene expression [2].
• STAT3 signaling promotes p16^INK4a^ and p21^Cip1^ expression, driving a stable senescent state that impairs TNF-α, IL-1β and IL-12 production upon LPS challenge [2].
• Genetic Nlrp3 knockout prevents immune senescence‑driven vascular aging in diabetic models, indicating that NLRP3 activity precedes tissue pathology [3].

Testable Predictions

1. In macrophages from old donors, inhibiting cGAS or STING will reduce phospho-STAT3 levels and SASP cytokines without altering NLRP3 inflammasome activity (as measured by ASC speck formation).
2. Adding oxidized mtDNA to young macrophages will recapitulate the aged phenotype: increased IL-6 trans‑signaling, STAT3 activation, and reduced TNF-α/IL-12 after LPS, an effect blocked by STING antagonists.
3. Genetic knockdown of gasdermin D in aged human macrophages will diminish mtDNA efflux, lower IL-6 trans‑signaling, and restore youthful cytokine profiles even when NLRP3 is pharmacologically activated.
4. In vivo, aged mice treated with a STING inhibitor will show improved survival after LPS challenge and elevated TNF-α/IL-12 levels, mirroring the effect of IL-6 knockout [2] but without altering IL-6 serum concentrations.

Experimental Design

Human cell work

• Isolate CD14+ monocytes from young (20‑30 yr) and old (65‑80 yr) donors, differentiate to macrophages with M‑CSF.
• Measure basal NLRP3 activity (ASC speck immunofluorescence, caspase-1 activity) and mtDNA in cytosol (qPCR for mtDNA‑nDNA ratio).
• Treat cells with: (a) NLRP3 inhibitor MCC950, (b) cGAS inhibitor RU.521, (c) STING inhibitor H‑151, (d) gasdermin D siRNA, (e) soluble IL-6R blockade.
• After 24 h, stimulate with LPS (100 ng/mL) for 4 h and quantify TNF-α, IL-1β, IL-12p70, IL-6 in supernatant (ELISA) and phospho-STAT3 (flow cytometry).
• Expected outcome: cGAS/STING or gasdermin D inhibition reduces phospho-STAT3 and SASP in old cells to young‑like levels, while NLRP3 inhibition only lowers IL-1β.

Mouse validation

• Use aged (18‑month) C57BL/6 mice; administer STING inhibitor H‑151 or vehicle for two weeks.
• Challenge with sub‑lethal LPS (5 mg/kg) and monitor survival, serum cytokines, and peritoneal macrophage phenotype.
• Parallel groups receive IL-6 neutralizing antibody to compare efficacy.
• Expected: STING inhibition improves survival and restores TNF-α/IL-12 to youthful levels without reducing circulating IL-6, indicating pathway separation.

Falsifiability

• If cGAS/STING or gasdermin D blockade fails to lower phospho-STAT3 or SASP in aged macrophages despite confirmed target engagement, the hypothesis is refuted.
• If mtDNA efflux does not correlate with IL-6 trans‑signaling (e.g., cytosolic mtDNA levels unchanged after gasdermin D knockdown), the proposed mechanistic link is invalid.

By positioning mtDNA‑cGAS‑STING as the key conduit between NLRP3 activation and IL-6‑driven SASP, this hypothesis provides a clear, testable route to reverse immunosenescence in humans while dissecting the contribution of each arm of the inflammatory axis.